Swissmedic Announces Limited Distribution Approval for Opdivo 40 mg/4 ml Infusion Concentrate Amid Supply Challenges

Swissmedic has issued a temporary authorization permitting the distribution of Opdivo 40 mg/4 ml Konzentrat zur…

Urgent Recall of Similasan Schnupfen Globuli Batch 17900 Announced by Swissmedic

On October 16, 2025, Swissmedic issued an urgent announcement regarding the recall of batch 17900 of…

Urgent Recall Issued for Nobivac DHPPi Veterinary Injection for Dogs

On October 15, 2025, Swissmedic announced a batch recall of the veterinary medicine Nobivac DHPPi, a…

Swissmedic Highlights Regulatory Focus on Parenteral Cosmetic Products

Swissmedic has released key insights on parenteral products in the cosmetic sector. This update, published on…

Swissmedic Grants First Authorization for Balversa® in Targeted Cancer Treatment

On October 10, 2025, Swissmedic issued its first authorization for Balversa®, marking a significant milestone in…

Swissmedic Approves Extended Use for Spevigo®: Important Regulatory Update

Swissmedic has officially approved an extension of the therapeutic indication for Spevigo®. This regulatory decision marks…

Swissmedic Grants Initial Authorization for Voxzogo®: A Milestone for Regulatory Compliance

Swissmedic, the Swiss agency for therapeutic products, has officially granted the first authorization for Voxzogo®, marking…

Swissmedic Announces First Authorization for Blenrep®

Swissmedic has officially announced the first authorization of Blenrep®, marking a significant regulatory milestone in its…

Swissmedic Opens Recruitment for Financial Leadership Role in Compliance-Focused Environment

Swissmedic, Switzerland’s authority responsible for the authorization and monitoring of therapeutic products, has announced a new…

Swissmedic Opens Clinical Assessor Positions: A Vital Role in Regulatory Oversight

Swissmedic has officially announced openings for Clinical Assessors within its Division of Clinical Assessment, offering employment…